Bioventus (BVS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Bioventus (BVS) do?
Bioventus Inc (BVS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells ultrasound bone healing devices and hyaluronic acid joint injections directly to healthcare providers. Manufactures non-surgical bone stimulation devices and injectable therapies for osteoarthritis joint pain. It is worth $838.40M on the market and sold $586.29M over the last year.
- Market cap
- $838.40M
- P/E ratio
- 12.3×
- Annual sales
- $586.29M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 13, 2026
Brands and businesses behind BVS
- Durolane: A single-injection hyaluronic acid treatment sold to clinicians to relieve joint pain caused by knee osteoarthritis.
- Exogen: An ultrasound device prescribed to patients to accelerate the healing of broken bones at home.
- Gelsyn-3: A three-injection hyaluronic acid therapy sold to orthopedic clinics for targeted knee osteoarthritis pain relief.
- Supartz FX: A multi-injection joint therapy prescribed for temporary relief of osteoarthritis symptoms in patients.
BVS’s flags, in plain English
Each flag is a number from Bioventus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Insiders Hold
Insiders own 30.8% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Wide Gross Margin
Gross margin of 67.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earns Its Keep
Earns 28.2% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Thinly Traded
Thinly traded, about 538 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about BVS
How big is Bioventus?
Bioventus’ market cap is $838.40M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $586.29M: what customers paid the company over the last year, before any costs.
What is BVS’s P/E ratio?
BVS’s P/E ratio is 12.3×. Investors pay about 12.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with BVS?
Elevated long-term debt generates substantial interest expenses that limit operating flexibility. That is one risk on Bioventus’ card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Bioventus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BVS’s filings on SEC.gov. The Margin Monkey is research, not advice.
